Skip to content

EBIT at other companies

Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
-$3.13M-342%
Journey Medical Corporation logo
Journey Medical CorporationDERM
-$1.49M+55.1%
Opko Health logo
Opko HealthOPK
-$51.02M+24.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$52.15M+1,073%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
HRO
HarrowHROW
-$22.08M-96.6%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Calculated from PTHS’s reported figures.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's EBIT?
PTHS (PTHS) reported EBIT of -$13.09M in Q1 2026.
How has PTHS's EBIT changed year-over-year?
PTHS's EBIT decreased by 613.6% year-over-year, from -$1.83M to -$13.09M.
What is the long-term trend for PTHS's EBIT?
Over 3 years (2022 to 2025), PTHS's EBIT has grown at a 141.0% compound annual growth rate (CAGR), from -$2.32M to -$32.43M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.